Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity - USD ($)
$ in Thousands
Total
IPO
Share Purchase Agreement
Common Stock
Common Stock
IPO
Common Stock
Share Purchase Agreement
Additional Paid-in Capital
Additional Paid-in Capital
IPO
Additional Paid-in Capital
Share Purchase Agreement
Accumulated Other Comprehensive Loss
Accumulated Deficit
Series A-1, A-2 and B Convertible Preferred Stock
Series A-1, A-2 and B Convertible Preferred Stock
Preferred Stock
Beginning balance at Dec. 31, 2019                         $ 86,544
Beginning balance (in shares) at Dec. 31, 2019                         28,615,546
Increase (Decrease) in Temporary Equity                          
Issuance of Series B convertible preferred stock, net of issuance costs                       $ 89,861  
Issuance of Series B convertible preferred stock, net of issuance costs (in shares)                         12,007,867
Conversion of preferred stock to common stock                       $ (176,405)  
Conversion of preferred stock to common stock (in shares)                         (40,623,413)
Ending balance at Dec. 31, 2020                         $ 0
Ending balance (in shares) at Dec. 31, 2020                         0
Beginning balance at Dec. 31, 2019 $ (88,016)     $ 0     $ 6,120       $ (94,136)    
Beginning balance (in shares) at Dec. 31, 2019       4,870,851                  
Increase (Decrease) in Stockholders' Equity                          
Conversion of preferred stock to common stock 176,405     $ 3     176,402            
Conversion of preferred stock to common stock (in shares)       21,958,588                  
Issuance of stock during the period new shares issued   $ 122,121     $ 1     $ 122,120          
Stock issued during the period shares new issues shares (in shares)         8,451,837                
Conversion of warrant liability to equity upon closing of initial public offering 114           114            
Issuance of common stock in connection with the cashless exercise of warrants       6,728                  
Issuance of common stock upon exercise of stock options 1,221           1,221            
Issuance of common stock upon exercise of stock options (in shares)       611,048                  
Issuance of warrants in connection with notes payable 188           188            
Vesting of restricted stock (in shares)       891,894                  
Stock-based compensation expense 2,961           2,961            
Unrealized losses on marketable securities (7)                 $ (7)      
Net loss (68,800)                   (68,800)    
Ending balance at Dec. 31, 2020 $ 146,187     $ 4     309,126     (7) (162,936)    
Ending balance (in shares) at Dec. 31, 2020 36,790,946     36,790,946                  
Ending balance at Dec. 31, 2021                         $ 0
Ending balance (in shares) at Dec. 31, 2021                         0
Increase (Decrease) in Stockholders' Equity                          
Issuance of stock during the period new shares issued     $ 42,205           $ 42,205        
Stock issued during the period shares new issues shares (in shares)           4,000,000              
Issuance of common stock upon exercise of stock options $ 1,418           1,418            
Issuance of common stock upon exercise of stock options (in shares) 508,774     508,774                  
Stock-based compensation expense $ 8,384           8,384            
Unrealized losses on marketable securities (3)                 (3)      
Net loss (101,320)                   (101,320)    
Ending balance at Dec. 31, 2021 $ 96,871     $ 4     $ 361,133     $ (10) $ (264,256)    
Ending balance (in shares) at Dec. 31, 2021 41,299,720     41,299,720